Vaya Pharma Introduces New Three-Month Supply Of Vayarin And Vayacog Medical Foods
BALTIMORE, May 02, 2017 (GLOBE NEWSWIRE) -- VAYA Pharma, a division of Enzymotec Ltd (NASDAQ:ENZY) and innovator of lipid-based medical foods, today announced the availability of new three-month bottles of its prescription medical foods Vayarin® and Vayacog®. The new product offerings, which are based on the recommended daily dosage found on the labels, will give patients the convenience and cost savings of multiple-month refills of Vayarin and Vayacog, which help manage the nutritional deficiencies associated with attention deficient hyperactivity disorder (ADHD) and early memory impairment (EMI), respectively. Three-month bottles of Vayarin and Vayacog are available exclusively through VAYA Direct – VAYA Pharma’s online fulfillment center – for $148.50.
“We are excited to expand our product portfolio and deliver a three-month supply of Vayarin and Vayacog in convenient packaging to help streamline refills for patients,” commented Rob Crim, CEO of VAYA Pharma. “Our hope is that the new three-month bottles will encourage patients to adhere to their care plan as Vayarin and Vayacog will be easier to refill and patients will experience a cost savings with the new, larger bottles.”
VAYA Pharma offers one-month bottles of Vayarin and Vayacog for $54.50 through VAYA Direct. To learn more or to change a future refill, please email VAYA Direct at order@vaya-direct.com or call toll free at 844-4-VDIRECT (844-483-4732).
To learn more about Vayarin and Vayacog, please visit www.vayarin.com and www.vayacog.com.
Vayarin® and Vayacog®
Vayarin and Vayacog are FDA-regulated prescription medical foods, clinically shown to safely and effectively manage nutritional deficiencies associated with ADHD and EMI, respectively. Vayarin helps to reduce ADHD behaviors and improve the quality of life in children. Vayacog helps to improve memory and cognitive abilities in adults with EMI. Vayarin and Vayacog, available in capsule form, are made of Generally Recognized as Safe (GRAS) ingredients.
VAYA Pharma
VAYA Pharma, a division of Enzymotec Ltd (NASDAQ:ENZY), is the innovator of lipid-based medical foods that are used to manage distinct nutritional deficiencies associated with certain diseases and health conditions, including attention deficit hyperactivity disorder (ADHD), early memory impairment (EMI) and hypertriglyceridemia. Committed to safety and efficacy, VAYA Pharma’s innovations – Vayarin®, Vayacog® and Vayarol® – are backed by years of clinical research. Its products are available in the U.S. by prescription for use under the supervision of a physician. VAYA Pharma is headquartered in Baltimore, Maryland. For more information, visit www.vayapharma.com.
Forward-Looking Statements
This press release may contain forward-looking statements related to VAYA Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. VAYA Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.
For more information: VAYA Pharma Shervin Esfahani 443.995.4299 ShervinE@vayapharma.com Andrea Martin (on behalf of VAYA Pharma) Andrea D. Martin Consulting, LLC 443.927.6183 andrea@consultmartin.com